Alfonso Zambon

15 Cotswold Road
London, ENG SM25NG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Expression of Concern: Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma.

Expression of Concern: Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma.

Journal: Cancer discovery

Published: December 18, 2025

Toward the Scale-Up of a Bicyclic Homopiperazine via Schmidt Rearrangement and Photochemical Oxaziridine Rearrangement in Continuous-Flow.

Toward the Scale-Up of a Bicyclic Homopiperazine via Schmidt Rearrangement and Photochemical Oxaziridine Rearrangement in Continuous-Flow.

Journal: Organic process research & development

Published: August 05, 2020

Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity Relationships.

Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity Relationships.

Journal: Journal of medicinal chemistry

Published: May 10, 2019

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma.

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma.

Journal: Cancer cell

Published: March 16, 2017

A novel protocol for the one-pot borylation/Suzuki reaction provides easy access to hinge-binding groups for kinase inhibitors.

A novel protocol for the one-pot borylation/Suzuki reaction provides easy access to hinge-binding groups for kinase inhibitors.

Journal: Organic & biomolecular chemistry

Published: December 02, 2015

Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.

Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.

Journal: Cancer cell

Published: May 17, 2014

BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling.

BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling.

Journal: Science signaling

Published: March 27, 2014

BRAF as a therapeutic target: a patent review (2006 - 2012).

BRAF as a therapeutic target: a patent review (2006 - 2012).

Journal: Expert opinion on therapeutic patents

Published: January 09, 2013

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.

Journal: Cancer discovery

Published: December 18, 2012

Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents.

Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents.

Journal: Bioorganic & medicinal chemistry

Published: October 24, 2012

Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma.

Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma.

Journal: The Journal of investigative dermatology

Published: August 17, 2012

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

Journal: The New England journal of medicine

Published: January 20, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026